INFU Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

36.68M

+8.36%

0.072

+80%

34.55M

-0.47%

0.026

-360%

37.09M

+3.02%

0.106

-11.67%

Estimates Revision

The market is revising Downward the revenue expectations for InfuSystem Holdings, Inc. (INFU) for FY2025, with the revenue forecasts being adjusted by -0.19% over the past three months. During the same period, the stock price has changed by -6.07%.

Revenue Estimates for FY2025

Revise Downward

-0.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+11.54%

In Past 3 Month

Stock Price

Go Down

-6.07%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast INFU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INFU is 13.67 USD with a low forecast of 12.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

12.00

Averages

13.67

High

15.00

Current: 0.000

Low

12.00

Averages

13.67

High

15.00

Roth Capital

Buy

maintain

$13 -> $14

2025-11-04

Reason

Roth Capital

Price Target

$13 -> $14

2025-11-04

maintain

Buy

Reason

Roth Capital raised the firm's price target on InfuSystem to $14 from $13 and keeps a Buy rating on the shares. The company's Q3 results were in-line with revenue expectations and above on earnings, with the core Oncology business in Patient Services continuing to perform and management remaining focused on executing opportunities that improve profitability, the analyst tells investors in a research note. The firm said that while it reduced its forward revenue expectations, it increased its adjusted EBITDA and EPS estimates slightly, with the higher estimates and lower share count from buybacks resulting in the new price target.

Lake Street

NULL -> Buy

initiated

$15

2025-09-22

Reason

Lake Street

Price Target

$15

2025-09-22

initiated

NULL -> Buy

Reason

Lake Street assumed coverage of InfuSystem with a Buy rating and a price target of $15, up from $12.50. The \"leading provider\" of infusion pumps and related services, operating under two complementary platforms of Patient Services and Device Solutions, is \"laying the groundwork for durable and profitable growth that investors may not fully appreciate today,\" the analyst argues.

Roth Capital

Kyle Bauser

Buy

initiated

$12

2025-07-21

Reason

Roth Capital

Kyle Bauser

Price Target

$12

2025-07-21

initiated

Buy

Reason

Roth Capital analyst Kyle Bauser initiated coverage of InfuSystem with a Buy rating and $12 price target. InfuSystem operates two key segments - Patient Services and Device Solutions - and the company's ability to automate billing, patient records, and pump tracking allows it to serve a larger base without linearly scaling headcount, the analyst tells investors. The firm believes the company can drive further margin expansion from more efficient operations and additional scale, the analyst added.

B. Riley

Buy

downgrade

$14 -> $12

2025-05-09

Reason

B. Riley

Price Target

$14 -> $12

2025-05-09

downgrade

Buy

Reason

B. Riley lowered the firm's price target on InfuSystem to $12 from $14 and keeps a Buy rating on the shares following the Q1 report. The company remains focused on improving profitability while pursuing growth opportunities such as advanced wound care and chemo mouthpiece, the analyst tells investors in a research note. Riley expects InfuSystem to continue to repurchase shares throughout the year.

Valuation Metrics

The current forward P/E ratio for InfuSystem Holdings Inc (INFU.A) is 25.27, compared to its 5-year average forward P/E of 77.53. For a more detailed relative valuation and DCF analysis to assess InfuSystem Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

77.53

Current PE

25.27

Overvalued PE

147.45

Undervalued PE

7.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.54

Current EV/EBITDA

6.29

Overvalued EV/EBITDA

12.38

Undervalued EV/EBITDA

6.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.75

Current PS

1.17

Overvalued PS

2.59

Undervalued PS

0.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 1158.53% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

INFU News & Events

Events Timeline

No data

News

7.5

2025-12-10Businesswire

InfuSystem Secures CMS Approval for Non-Opioid Payment

7.5

2025-12-10Newsfilter

InfuSystem Secures CMS Approval for Separate Payment of Two Infusion Pumps

1.0

2025-11-10Newsfilter

InfuSystem to Attend the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025

People Also Watch

Frequently Asked Questions

What is InfuSystem Holdings Inc (INFU) stock price today?

The current price of INFU is 8.67 USD — it has decreased -3.34 % in the last trading day.

What is InfuSystem Holdings Inc (INFU)'s business?

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

What is the price predicton of INFU Stock?

What is InfuSystem Holdings Inc (INFU)'s revenue for the last quarter?

InfuSystem Holdings Inc revenue for the last quarter amounts to 36.49M USD, increased 3.31 % YoY.

What is InfuSystem Holdings Inc (INFU)'s earnings per share (EPS) for the last quarter?

InfuSystem Holdings Inc. EPS for the last quarter amounts to 0.11 USD, increased 37.50 % YoY.

What changes have occurred in the market's expectations for InfuSystem Holdings Inc (INFU)'s fundamentals?

How many employees does InfuSystem Holdings Inc (INFU). have?

InfuSystem Holdings Inc (INFU) has 502 emplpoyees as of January 10 2026.

What is InfuSystem Holdings Inc (INFU) market cap?

Today INFU has the market capitalization of 176.31M USD.